Utilization of the fibroscan in community-based clinics
View File(s)
- Author(s)
- Details
-
Anna Marie Hefner, RN, MaEd, CPNP; Renee Pozza, RN, CNS, CFNP. FAASLD; Tarek I. Hassanein, FACP, FACG, AGAF
- Sigma Affiliation
- Iota Sigma
Visitor Statistics
Visits vs Downloads
Visitors - World Map
Top Visiting Countries
Country | Visits |
---|
Top Visiting Cities
City | Visits |
---|
Visits (last 6 months)
Downloads (last 6 months)
Popular Works for Hefner, Anna Marie by View
Title | Page Views |
---|
Popular Works for Hefner, Anna Marie by Download
Title | Downloads |
---|
View Citations
Citations
Session presented on Saturday, July 23, 2016 and Sunday, July 24, 2016:
Purpose: The purpose of the presentation is to disseminate knowledge of the benefits of the Fibroscan technology for patient care decisions in patients with liver disease. Identification of staging of fibrosis impacts the care of the patient with liver disease. The Fibroscan technology measures the stiffness (fibrosis) based on the velocity of transmission of a shear wave through the liver, created by a vibratory source. Currently, this technique has been used most consistently in patients with chronic HCV. Though the liver biopsy has been the 'gold' standard to stage liver fibrosis, it remains an invasive test with sampling error. With the recent advances in hepatitis C therapy and the increased awareness of fatty liver disease, more patients are currently screened for the presence of chronic liver disease. In order to facilitate treatment decisions with patients based on disease severity, the Fibroscan technology has been utilized. The Food and Drug Administration (FDA) recently approved this technology, however, it has been used for many years in Europe to evaluate liver fibrosis. In order to determine the effectiveness and feasibility of this new technology a Fibroscan machine was purchased by a community clinic treating individuals with liver disease in Southern California. The etiology of liver disease was 84.7% hepatitis C, 9.2% fatty liver, 2.4% HBV, 0.1% Alcoholic liver disease, and 3.6% others.
Methods: The Southern California Liver Centers developed a Fibrosis Program in order to determine underlying disease severity in patients diagnosed with liver disease. Patients were referred by primary care providers to the Program for a fibroscan if diagnosed with chronic liver disease. SCLC Personnel were trained and certified in the technique of fibroscan through ECHOscan. Between May 2013 and October 2015, 1088 patients were referred to the Fibrosis Program for assessment.
Results: A total of 1341 fibroscans were performed from May 2013 to present. Demographics of the patients include: male 795 (57%) and female 576 (43%). The etiology of liver disease was 84.7% hepatitis C, 9.2% fatty liver, 2.4% HBV, 0.1% Alcoholic liver disease, and 3.6% others. The majority of patients referred for fibroscans were patients with hepatitis C (HCV) (n=1088, 84.7%) and were related to evaluation for potential HCV treatment. There were 654 males (60.1%) and 434 females (39.9%). The insurance companies are the driving force for the use of fibroscan for staging of fibrosis for treatment in HCV. Of the patients with a diagnosis of HCV, 80% were born between the year 1945-1965, or babyboomers. Advanced fibrosis/cirrhosis was found in 50.8% of the HCV patients, indicating the need for continued follow up of their liver disease upon completion and cure of HCV. For those individuals with a diagnosis of fatty liver disease, a total of 117 fibroscans were completed. There was 42 males (40%) and 75 females (60%). Advanced fibrosis/cirrhosis was found in 38.5% of the patients with fatty liver disease. However, a liver biopsy was still required for the diagnosis of non-alcoholic steatohepatitis (NASH). Comparative fibroscan and liver biopsy results are being analyzed.
Conclusion: The use of elastography performed by Fibroscan, in the community setting allows for rapid, readily available sensitive tool to assess the severity of fibrosis in patients with chronic liver disease and a decrease need for a liver biopsy. The data underscores the importance of staging patients irrespective of age groups and disease entity. Patients and providers were eager to utilize the new technology for disease severity evaluation. Fibroscan will separate patients with no to minimal fibrosis from those with advanced fibrosis and cirrhosis. The clinician has instantaneous results to assist in making decisions during the patient's visit. Given a choice, the patients prefer fibroscan over liver biopsy. As additional studies are conducted, the establishment of this technique will continue to evaluate hepatic fibrosis in patients with chronic liver disease.
Theme: Leading Global Research: Advancing Practice, Advocacy, and Policy
Items submitted to a conference/event were evaluated/peer-reviewed at the time of abstract submission to the event. No other peer-review was provided prior to submission to the Henderson Repository.
Type | Poster |
Acquisition | Proxy-submission |
Review Type | Abstract Review Only: Reviewed by Event Host |
Format | Text-based Document |
Evidence Level | N/A |
Research Approach | N/A |
Keywords | Fibroscan; Staging of Liver Fibrosis; Chronic Liver Disease |
Name | 27th international Nursing Research Congress |
Host | Sigma Theta Tau international |
Location | Cape Town, South Africa |
Date | 2016 |
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Related items
Showing items related by title, author, creator and subjects.
-
Community awareness: Nutritional patterns
Pusztai, Julia; Hassanein, Tarek I.; Hefner, Anna Marie; Heinlein, Catherine; Pozza, Renee (2012-9-12)Purpose: The purpose of this study was to analyze the reported diets of clients in a community wellness center. The Hispanic population is at higher risk for the development of fatty liver disease. It is correlated with ... -
HALO: Health and Liver Optimization, partners in care
Pozza, Renee; Hefner, Anna Marie; Hassanein, Tarek I. (2016-07-13)Session presented on Sunday, July 24, 2016: Purpose: The purpose of the presentation is to disseminate knowledge and effectiveness of a unique model of patient care in chronic disease management. The Health and Liver ... -
Working with the obese client: Helping achieve lifestyle changes to meet their weight loss goals
Hefner, Anna Marie; Pozza, Renee; Hassanein, Tarek I.; Hill, Catherine McCoy (2017-07-27)The central issue to achieving and maintaining weight loss is changing one's behaviors. Change theory and motivational interviewing provide tools and techniques in helping clients meet weight loss goals. In this retrospective ... -
Importance of palliative care in end-stage liver disease: A rising global issue
Pozza, Renee; Huiskes, Bonita; Hefner, Anna Marie (2017-07-28)The disease and management of end stage liver disease is a complex issue requiring a multi-disciplinary team approach. Often these individuals seek care from a variety of providers with resulting fragmentation and variable ... -
Community-based wellness center: Getting people to move
Pusztai, Julia; Hefner, Anna Marie; Heinlein, Catherine (2012-9-12)Purpose: The purpose of this study was to increase the physical activity in low income Hispanic men and women in a community center. With the increase in obesity rates, physical activity plays a central role in overall ...